UA73076C2 - Aqueous aerosol preparations containing biologically active macromolecules and method for their manufacture - Google Patents
Aqueous aerosol preparations containing biologically active macromolecules and method for their manufacture Download PDFInfo
- Publication number
- UA73076C2 UA73076C2 UA2000031252A UA2000031252A UA73076C2 UA 73076 C2 UA73076 C2 UA 73076C2 UA 2000031252 A UA2000031252 A UA 2000031252A UA 2000031252 A UA2000031252 A UA 2000031252A UA 73076 C2 UA73076 C2 UA 73076C2
- Authority
- UA
- Ukraine
- Prior art keywords
- aqueous aerosol
- preparation according
- aerosol preparation
- active substance
- insulin
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 229920002521 macromolecule Polymers 0.000 title abstract description 19
- 238000000034 method Methods 0.000 title description 22
- 238000004519 manufacturing process Methods 0.000 title description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 68
- 102000004877 Insulin Human genes 0.000 claims description 34
- 108090001061 Insulin Proteins 0.000 claims description 34
- 108010050904 Interferons Proteins 0.000 claims description 34
- 102000014150 Interferons Human genes 0.000 claims description 34
- 229940125396 insulin Drugs 0.000 claims description 34
- 239000013543 active substance Substances 0.000 claims description 28
- 229940079322 interferon Drugs 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 238000005507 spraying Methods 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 102000018997 Growth Hormone Human genes 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- -1 leptins Proteins 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 102000000412 Annexin Human genes 0.000 claims description 2
- 108050008874 Annexin Proteins 0.000 claims description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
- 101800004538 Bradykinin Proteins 0.000 claims description 2
- 102400000967 Bradykinin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000002512 Orexin Human genes 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 108010001957 Ularitide Proteins 0.000 claims description 2
- 102400001279 Urodilatin Human genes 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229960002520 hepatitis vaccine Drugs 0.000 claims description 2
- 102000002467 interleukin receptors Human genes 0.000 claims description 2
- 108010093036 interleukin receptors Proteins 0.000 claims description 2
- 229940076144 interleukin-10 Drugs 0.000 claims description 2
- 229940117681 interleukin-12 Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 229940041323 measles vaccine Drugs 0.000 claims description 2
- 108060005714 orexin Proteins 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 235000013930 proline Nutrition 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims 2
- 229960001319 parathyroid hormone Drugs 0.000 claims 2
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 229960000258 corticotropin Drugs 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 239000007789 gas Substances 0.000 abstract description 6
- 239000003380 propellant Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 52
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 22
- 229960000257 tiotropium bromide Drugs 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 17
- 108010045648 interferon omega 1 Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000007246 mechanism Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 9
- 229940047124 interferons Drugs 0.000 description 9
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 9
- 239000006199 nebulizer Substances 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19733651A DE19733651A1 (de) | 1997-08-04 | 1997-08-04 | Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole |
| PCT/EP1998/004803 WO1999007340A1 (de) | 1997-08-04 | 1998-07-31 | Wässrige aerosolzubereitungen enthaltend biologisch aktive makromoleküle und verfahren zur erzeugung entsprechender aerosole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73076C2 true UA73076C2 (en) | 2005-06-15 |
Family
ID=7837935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000031252A UA73076C2 (en) | 1997-08-04 | 1998-07-31 | Aqueous aerosol preparations containing biologically active macromolecules and method for their manufacture |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20030064032A1 (ru) |
| EP (2) | EP1527771A3 (ru) |
| JP (1) | JP2001513492A (ru) |
| KR (1) | KR20010022636A (ru) |
| CN (1) | CN1177581C (ru) |
| AR (1) | AR016581A1 (ru) |
| AT (1) | ATE301987T1 (ru) |
| AU (1) | AU753673B2 (ru) |
| BG (1) | BG64966B1 (ru) |
| BR (1) | BR9811827A (ru) |
| CA (1) | CA2297174A1 (ru) |
| CO (1) | CO4960637A1 (ru) |
| DE (2) | DE19733651A1 (ru) |
| DK (1) | DK1003478T3 (ru) |
| EA (1) | EA002255B1 (ru) |
| EE (1) | EE05053B1 (ru) |
| ES (1) | ES2248915T3 (ru) |
| HK (1) | HK1027749A1 (ru) |
| HR (1) | HRP980425B1 (ru) |
| HU (1) | HUP0003805A3 (ru) |
| ID (1) | ID24200A (ru) |
| IL (2) | IL134115A0 (ru) |
| MY (1) | MY132852A (ru) |
| NO (1) | NO20000553L (ru) |
| NZ (1) | NZ503160A (ru) |
| PL (1) | PL338421A1 (ru) |
| PT (1) | PT1003478E (ru) |
| RS (1) | RS49705B (ru) |
| SI (1) | SI1003478T1 (ru) |
| SK (1) | SK285637B6 (ru) |
| TR (1) | TR200000312T2 (ru) |
| TW (1) | TWI222887B (ru) |
| UA (1) | UA73076C2 (ru) |
| UY (1) | UY25122A1 (ru) |
| WO (1) | WO1999007340A1 (ru) |
| ZA (1) | ZA986931B (ru) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030215396A1 (en) | 1999-09-15 | 2003-11-20 | Boehringer Ingelheim Pharma Kg | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
| US7963955B2 (en) | 1998-02-27 | 2011-06-21 | Boehringer Ingelheim International Gmbh | Container for a medicinal liquid |
| SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| RU2140285C1 (ru) * | 1999-01-25 | 1999-10-27 | Гапонюк Петр Яковлевич | Противовирусное средство - капли в нос "гриппферон" |
| US6350432B1 (en) * | 1999-03-19 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Pressurized container having an aerosolized pharmaceutical composition |
| NZ519403A (en) * | 2001-06-21 | 2005-03-24 | Pfizer Prod Inc | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels |
| DE102004001451A1 (de) * | 2004-01-08 | 2005-08-11 | Boehringer Ingelheim International Gmbh | Vorrichtung zum Haltern eines fluidischen Bauteiles |
| DE102004011381A1 (de) | 2004-03-05 | 2005-09-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Impaktionsdüse für treibgasbetriebene Dosieraerosole |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| DE102005024439A1 (de) | 2005-05-24 | 2006-12-07 | Boehringer Ingelheim International Gmbh | Zerstäuber |
| DE102005029746B4 (de) | 2005-06-24 | 2017-10-26 | Boehringer Ingelheim International Gmbh | Zerstäuber |
| US20100074911A1 (en) * | 2005-06-27 | 2010-03-25 | Felicity Cutts | Vaccine nebulizers |
| ME01610B (me) | 2005-08-24 | 2014-09-20 | Boehringer Ingelheim Int | Atomizer koji sadrži brojač i blokadu daljeg aktiviranja |
| DE102006009637A1 (de) | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalator mit Mundstück mit mikrobiologischer Schutzfunktion |
| AU2005338631B2 (en) * | 2005-11-30 | 2011-12-01 | Generex Pharmaceuticals Inc. | Orally absorbed pharmaceutical formulation and method of administration |
| EP1792660A1 (en) | 2005-12-02 | 2007-06-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device |
| DE102006014433A1 (de) | 2006-03-27 | 2007-10-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dosieraerosole für die Verabreichung von pharmazeutischen Zubereitungen |
| DE102006016903A1 (de) | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalator |
| DE102006016901A1 (de) | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mundstück für einen Inhalator |
| US7841338B2 (en) | 2006-04-13 | 2010-11-30 | Boehringer Ingelheim International Gmbh | Dispensing device |
| EP1844807A1 (de) | 2006-04-13 | 2007-10-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medikamentenmagazin, sowie Vorrichtung und Verfahren zum Öffnen desselben; Mehrdosispulverinhalator |
| EP1844808A1 (de) | 2006-04-13 | 2007-10-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medikamenten-Ausgabevorrichtung |
| EP1844809A1 (de) | 2006-04-13 | 2007-10-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Medikamentenmagazin für einen Inhalator, sowie Mehrdosispulverinhalator |
| DE102006022002A1 (de) | 2006-05-10 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Zerstäuber und Verfahren zur Zerstäubung von Fluid |
| DE102006043637A1 (de) | 2006-05-18 | 2007-11-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Zerstäuber |
| US8061350B2 (en) | 2006-06-02 | 2011-11-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process and device for dosing pharmaceutical agents |
| DE102007020578A1 (de) | 2007-05-02 | 2008-11-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Wässrige Aerosolzubereitungen enthaltend therapeutisch wirksame Mikroorganismen oder Teile von Mikroorganismen und Verfahren zur Erzeugung entsprechender Aerosole |
| DE102007023012A1 (de) | 2007-05-15 | 2008-11-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Zerstäuber und Filter |
| JP5504156B2 (ja) | 2007-06-15 | 2014-05-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 吸入器 |
| EP2011536A1 (en) | 2007-07-06 | 2009-01-07 | Boehringer Ingelheim Pharma GmbH & Co. KG | Inhaler |
| CN100593424C (zh) * | 2007-07-18 | 2010-03-10 | 北京万生药业有限责任公司 | 一种氧气湿化及输送装置 |
| DE102007033861A1 (de) | 2007-07-20 | 2009-07-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverinhalator |
| DE102007036411A1 (de) | 2007-07-20 | 2009-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverinhalator |
| DE102007033860A1 (de) | 2007-07-20 | 2009-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Prüfvorrichtung |
| DE102007034156A1 (de) | 2007-07-21 | 2009-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Vorrichtung und Verfahren zur Bestimmung des Feuchtegehalts eines Verpackungsmaterials |
| DE102007036413A1 (de) | 2007-08-02 | 2009-02-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Vorrichtung und Verfahren zur Bestimmung des Feuchtegehalts eines Verpackungsmaterials |
| DE102007052871A1 (de) | 2007-11-02 | 2009-05-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kapsel zur Aufnahme von pharmazeutischen Wirkstoffformulierungen |
| DE102007058112A1 (de) | 2007-12-03 | 2009-06-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverinhalator mit Wirkstofftablette |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| EP2254704B1 (en) | 2008-03-17 | 2016-10-19 | Boehringer Ingelheim International GmbH | Reservoir and nebulizer |
| EP2135632A1 (de) | 2008-06-20 | 2009-12-23 | Boehringer Ingelheim International Gmbh | Inhalator |
| EP2198972A1 (de) | 2008-12-18 | 2010-06-23 | Boehringer Ingelheim International GmbH | Reservoir und Zerstäuber |
| WO2010076012A1 (de) | 2009-01-02 | 2010-07-08 | Boehringer Ingelheim International Gmbh | Bauteil und inhalator sowie verfahren zur herstellung eines bauteils |
| EP2408571B1 (de) | 2009-03-17 | 2015-09-16 | Boehringer Ingelheim International GmbH | Reservoir und zerstäuber |
| EP2408500B1 (en) | 2009-03-17 | 2015-04-29 | Boehringer Ingelheim International GmbH | Dispensing device, and storage device for dispensing a formulation |
| EP2414560B1 (de) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Verfahren zur beschichtung einer oberfläche eines bauteils |
| JP5812354B2 (ja) | 2009-04-28 | 2015-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 吸入器具 |
| JP5763053B2 (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ |
| CN104799969B (zh) | 2009-06-25 | 2018-11-06 | 贝林格尔·英格海姆维特梅迪卡有限公司 | 吸入器 |
| US8746244B2 (en) | 2009-10-02 | 2014-06-10 | Boehringer Ingelheim International Gmbh | Powder inhaler |
| JP5658268B2 (ja) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2011064164A1 (en) | 2009-11-25 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2011160932A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| CN103386125A (zh) * | 2012-05-08 | 2013-11-13 | 刘江秋 | 肾综合征出血热鼻黏膜免疫气溶胶疫苗的研制 |
| JP6643231B2 (ja) | 2013-08-09 | 2020-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| EP2835146B1 (en) | 2013-08-09 | 2020-09-30 | Boehringer Ingelheim International GmbH | Nebulizer |
| CN103575718A (zh) * | 2013-11-21 | 2014-02-12 | 中国人民解放军63975部队 | 用量子点荧光传感体系测定蛋白喷剂雾化效果的方法 |
| PL3139984T3 (pl) | 2014-05-07 | 2021-11-08 | Boehringer Ingelheim International Gmbh | Nebulizator |
| LT3928818T (lt) | 2014-05-07 | 2023-03-27 | Boehringer Ingelheim International Gmbh | Purkštuvas ir talpa |
| JP6580070B2 (ja) | 2014-05-07 | 2019-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 容器、ネブライザ、及び使用 |
| CN104474534A (zh) * | 2014-12-22 | 2015-04-01 | 哈德逊（天津）生物技术有限责任公司 | 白介素-18抗病毒口腔喷剂 |
| EP3563894B1 (en) | 2018-05-04 | 2021-12-22 | Boehringer Ingelheim International GmbH | Nebulizer and container |
| JP2023543965A (ja) * | 2020-08-14 | 2023-10-19 | イスタンブル ウニヴェルシテシ レクトールルグ | 吸入経路を介するソフトミスト吸入器又は振動メッシュ式ネブライザーによるウイルス性肺疾患、急性及び／又は慢性の肺疾患治療におけるヘパリン組成物の使用 |
| CN114712336B (zh) * | 2020-12-22 | 2023-11-07 | 黄嘉若 | 一种用于肺部给药的水性气溶胶、制备方法和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4153689A (en) * | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
| EP0083619A1 (en) * | 1981-07-17 | 1983-07-20 | Nordisk Insulinlaboratorium | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
| EP0102976A1 (en) * | 1982-03-03 | 1984-03-21 | Nordisk Insulinlaboratorium | A process for producing an insulin preparation |
| US4476116A (en) * | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| DE3827121A1 (de) * | 1988-08-10 | 1990-02-15 | Hoechst Ag | Verfahren zur herstellung von des-b30-insulinen und des-b30-insulinderivaten |
| AU5194990A (en) * | 1989-02-23 | 1990-09-26 | Rorer International (Holdings), Inc. | Therapeutic aerosol formulations |
| JP2704546B2 (ja) * | 1989-04-04 | 1998-01-26 | 光利 太良 | Ａｔｌｌ治療用吸入剤 |
| SG45171A1 (en) * | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| US5230884A (en) * | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| CA2082951C (en) * | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
| DE4117078A1 (de) * | 1991-05-25 | 1992-11-26 | Boehringer Ingelheim Kg | Verfahren zur herstellung therapeutisch anwendbarer aerosole |
| US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| DE69431290D1 (de) * | 1993-02-12 | 2002-10-10 | Avant Immunotherapeutics Inc | PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1 |
| IL109112A0 (en) * | 1993-03-24 | 1994-06-24 | Boehringer Ingelheim Pharma | Pharmaceutical compositions containing human manganese superoxide dismutase |
| NZ271181A (en) * | 1993-07-19 | 1998-06-26 | Amgen Inc | Protein protection; method for stabilising aerosolised proteins by adding a water-soluble polar organic compound to the aqueous solution prior to aerosolisation |
| JPH07165613A (ja) * | 1993-10-19 | 1995-06-27 | Dot:Kk | 経鼻吸収薬物用キャリヤおよび生理活性ペプチド組成物 |
| JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| US5541569A (en) * | 1995-02-28 | 1996-07-30 | Jang; Huey J. | Switch having a circuit breaker |
| DE19536902A1 (de) * | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| US5780440A (en) * | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
-
1997
- 1997-08-04 DE DE19733651A patent/DE19733651A1/de not_active Ceased
-
1998
- 1998-07-31 TR TR2000/00312T patent/TR200000312T2/xx unknown
- 1998-07-31 DK DK98943814T patent/DK1003478T3/da active
- 1998-07-31 PT PT98943814T patent/PT1003478E/pt unknown
- 1998-07-31 PL PL98338421A patent/PL338421A1/xx not_active Application Discontinuation
- 1998-07-31 CN CNB988078953A patent/CN1177581C/zh not_active Expired - Fee Related
- 1998-07-31 EP EP05002747A patent/EP1527771A3/de not_active Withdrawn
- 1998-07-31 CA CA002297174A patent/CA2297174A1/en not_active Abandoned
- 1998-07-31 KR KR1020007001230A patent/KR20010022636A/ko not_active Application Discontinuation
- 1998-07-31 HU HU0003805A patent/HUP0003805A3/hu unknown
- 1998-07-31 EE EEP200000065A patent/EE05053B1/xx not_active IP Right Cessation
- 1998-07-31 BR BR9811827-7A patent/BR9811827A/pt not_active Application Discontinuation
- 1998-07-31 DE DE59813014T patent/DE59813014D1/de not_active Expired - Lifetime
- 1998-07-31 AU AU91577/98A patent/AU753673B2/en not_active Ceased
- 1998-07-31 WO PCT/EP1998/004803 patent/WO1999007340A1/de not_active Application Discontinuation
- 1998-07-31 ES ES98943814T patent/ES2248915T3/es not_active Expired - Lifetime
- 1998-07-31 RS YUP-56/00A patent/RS49705B/sr unknown
- 1998-07-31 UA UA2000031252A patent/UA73076C2/uk unknown
- 1998-07-31 EA EA200000190A patent/EA002255B1/ru not_active IP Right Cessation
- 1998-07-31 ID IDW20000210A patent/ID24200A/id unknown
- 1998-07-31 EP EP98943814A patent/EP1003478B1/de not_active Expired - Lifetime
- 1998-07-31 SI SI9830799T patent/SI1003478T1/sl unknown
- 1998-07-31 AT AT98943814T patent/ATE301987T1/de active
- 1998-07-31 SK SK150-2000A patent/SK285637B6/sk not_active IP Right Cessation
- 1998-07-31 NZ NZ503160A patent/NZ503160A/en unknown
- 1998-07-31 IL IL13411598A patent/IL134115A0/xx active IP Right Grant
- 1998-07-31 JP JP2000506934A patent/JP2001513492A/ja active Pending
- 1998-08-03 HR HR980425A patent/HRP980425B1/xx not_active IP Right Cessation
- 1998-08-03 UY UY25122A patent/UY25122A1/es not_active IP Right Cessation
- 1998-08-03 MY MYPI98003548A patent/MY132852A/en unknown
- 1998-08-03 CO CO98044242A patent/CO4960637A1/es unknown
- 1998-08-03 AR ARP980103825A patent/AR016581A1/es not_active Suspension/Interruption
- 1998-08-03 ZA ZA9806931A patent/ZA986931B/xx unknown
-
1999
- 1999-03-12 TW TW087112723A patent/TWI222887B/zh not_active IP Right Cessation
-
2000
- 2000-01-18 IL IL134115A patent/IL134115A/en not_active IP Right Cessation
- 2000-02-03 NO NO20000553A patent/NO20000553L/no not_active Application Discontinuation
- 2000-02-04 BG BG104130A patent/BG64966B1/bg active Active
- 2000-10-26 HK HK00106819A patent/HK1027749A1/xx not_active IP Right Cessation
-
2002
- 2002-11-06 US US10/288,770 patent/US20030064032A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73076C2 (en) | Aqueous aerosol preparations containing biologically active macromolecules and method for their manufacture | |
| US20110268668A1 (en) | Process for nebulizing aqueous compositions containing highly concentrated insulin | |
| AU2022200010B2 (en) | Heat-stable dry powder pharmaceutical compositions and methods | |
| KR100466486B1 (ko) | 에어러졸화된약제의폐전달 | |
| BG105377A (bg) | Доставяне на аерозолен активен агент с модулиранаустойчивост на потока | |
| KR101750032B1 (ko) | 건성 분무기 엘리먼트들의 식별 | |
| BG65091B1 (bg) | Устройство за доставяне на аерозолен активен агент | |
| CA2558426A1 (en) | Formulations decreasing particle exhalation | |
| US20040009231A1 (en) | hGH (human growth hormone) formulations for pulmonary administration | |
| US20210403550A1 (en) | Formulation of tocilizumab and method for treating covid-19 by inhalation | |
| AU2002300833B2 (en) | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols | |
| CZ2000428A3 (cs) | Vodný aerosolový prostředek pro inhalaci | |
| MXPA00001171A (en) | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols | |
| US20220152157A1 (en) | Compositions for the treatment of viral pulmonary infections |